Anticoagulation Length in Cancer Associated Thrombosis

Phase 2 Terminated 2 enrolled Cardiff University National Institute for Health Research, United Kingdom · collab Wales Cancer Trials Unit · collab

RandomizedParallel-groupOpen-labelSupportive care

Summary

This is a two year, multicentre, mixed methods feasibility study including a randomised controlled two-arm interventional trial, a nested qualitative study, focus groups and a United Kingdom (UK) wide survey exercise.

Timeline

Start: 2013-12
Primary completion: 2015-02
Completion: 2015-02

Publications

Results Noble SI, Nelson A, Fitzmaurice D, Bekkers MJ, Baillie J, Sivell S, Canham J, Smith JD, Casbard A, Cohen A, Cohen D, Evans J, Fletcher K, Johnson M, Maraveyas A, Prout H, Hood K. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technol Assess. 2015 Oct;19(83):vii-xxiii, 1-93. doi: 10.3310/hta19830.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dalteparin sodium	Other / unclassified	—	Other
Subject	Enoxaparin sodium	Other / unclassified	—	Other
Subject	Tinzaparin	Other / unclassified	—	Other

Anticoagulation Length in Cancer Associated Thrombosis

Summary

Timeline

Publications

Drugs

Indications